MED21

Summary

MED21 (mediator complex subunit 21, HGNC:11473) is a protein-coding gene on chromosome 12p11.23, encoding Mediator of RNA polymerase II transcription subunit 21 (Q13503). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. It is a selective cancer dependency (DepMap: 83.4% of cell lines).

This gene encodes a member of the mediator complex subunit 21 family. The encoded protein interacts with the human RNA polymerase II holoenzyme and is involved in transcriptional regulation of RNA polymerase II transcribed genes. A pseudogene of this gene is located on chromosome 8. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9412 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 14 total
• Cancer dependency (DepMap): dependent in 83.4% of screened cell lines
• MANE Select transcript: NM_004264

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11473
Approved symbol	MED21
Name	mediator complex subunit 21
Location	12p11.23
Locus type	gene with protein product
Status	Approved
Aliases	SRB7
Ensembl gene	ENSG00000152944
Ensembl biotype	protein_coding
OMIM	603800
Entrez	9412

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000282892, ENST00000536503, ENST00000536711, ENST00000538186, ENST00000544998, ENST00000546323, ENST00000621885, ENST00000924664, ENST00000924665, ENST00000943693

RefSeq mRNA: 2 — MANE Select: NM_004264 NM_001271811, NM_004264

CCDS: CCDS8711

Canonical transcript exons

ENST00000282892 — 4 exons

Exon	Start	End
ENSE00001133102	27028285	27030673
ENSE00003480494	27027347	27027447
ENSE00003483219	27026420	27026534
ENSE00003687374	27022558	27022621

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 97.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.8736 / max 383.8826, expressed in 1806 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
124827	32.8736	1806

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.38	gold quality
oocyte	CL:0000023	96.35	gold quality
calcaneal tendon	UBERON:0003701	95.68	gold quality
cortical plate	UBERON:0005343	93.36	gold quality
islet of Langerhans	UBERON:0000006	92.73	gold quality
tendon	UBERON:0000043	92.59	gold quality
adrenal tissue	UBERON:0018303	92.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.96	gold quality
heart right ventricle	UBERON:0002080	91.46	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.27	gold quality
ganglionic eminence	UBERON:0004023	91.18	gold quality
popliteal artery	UBERON:0002250	90.79	gold quality
tibial artery	UBERON:0007610	90.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.54	gold quality
biceps brachii	UBERON:0001507	90.42	gold quality
aorta	UBERON:0000947	90.36	gold quality
muscle of leg	UBERON:0001383	90.35	gold quality
descending thoracic aorta	UBERON:0002345	90.29	gold quality
renal glomerulus	UBERON:0000074	90.24	gold quality
right adrenal gland	UBERON:0001233	90.22	gold quality
left adrenal gland	UBERON:0001234	90.19	gold quality
gastrocnemius	UBERON:0001388	90.13	gold quality
right testis	UBERON:0004534	90.08	gold quality
ventricular zone	UBERON:0003053	90.06	gold quality
thoracic aorta	UBERON:0001515	89.98	gold quality
rectum	UBERON:0001052	89.94	gold quality
right adrenal gland cortex	UBERON:0035827	89.94	gold quality
testis	UBERON:0000473	89.90	gold quality
ascending aorta	UBERON:0001496	89.86	gold quality
right coronary artery	UBERON:0001625	89.86	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	3.45
E-MTAB-4850	no	183.30
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TBP

miRNA regulators (miRDB)

91 targeting MED21, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-944	99.82	70.85	3042

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 83.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• Co-expressed yeast MED21 and MED7 in E. coli to determine structure. (PMID:15710619)
• Blocking MED1/MED21 expression caused hyperproliferation of keratinocytes (PMID:20520624)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	med21	ENSDARG00000026839
mus_musculus	Med21	ENSMUSG00000030291
rattus_norvegicus	Med21	ENSRNOG00000001820
drosophila_melanogaster	MED21	FBGN0040020
caenorhabditis_elegans		WBGENE00007704

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 21 — Q13503 (reviewed: Q13503)

Alternative names: Mediator complex subunit 21, RNA polymerase II holoenzyme component SRB7

All UniProt accessions (4): Q13503, A0A024RAW0, F5GZQ1, F5H872

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

Subunit / interactions. Interacts with PPARG. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. Interacts with THRA in a ligand-dependent fashion.

Subcellular location. Nucleus.

Similarity. Belongs to the Mediator complex subunit 21 family.

RefSeq proteins (2): NP_001258740, NP_004255* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021384	Mediator_Med21	Family
IPR037212	Med7/Med21-like	Homologous_superfamily

Pfam: PF11221

UniProt features (5 total): helix 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
7EMF	ELECTRON MICROSCOPY	3.5
8TRH	ELECTRON MICROSCOPY	3.7
7ENA	ELECTRON MICROSCOPY	4.07
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7ENJ	ELECTRON MICROSCOPY	4.4
7NVR	ELECTRON MICROSCOPY	4.5
8T9D	ELECTRON MICROSCOPY	4.66
7LBM	ELECTRON MICROSCOPY	4.8
8GXQ	ELECTRON MICROSCOPY	5.04
8TQW	ELECTRON MICROSCOPY	8.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13503-F1	85.25	0.60

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways
R-HSA-9843745	Adipogenesis

MSigDB gene sets: 208 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, BROWNE_HCMV_INFECTION_6HR_DN, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, PUJANA_CHEK2_PCC_NETWORK, chr12p11, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP, GOBP_BLASTOCYST_DEVELOPMENT, GOBP_MAINTENANCE_OF_CELL_NUMBER, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

GO Biological Process (8): blastocyst development (GO:0001824), regulation of transcription by RNA polymerase II (GO:0006357), protein ubiquitination (GO:0016567), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), somatic stem cell population maintenance (GO:0035019), positive regulation of transcription by RNA polymerase II (GO:0045944), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261)

GO Molecular Function (5): transcription coregulator activity (GO:0003712), transcription coactivator activity (GO:0003713), DNA-directed RNA polymerase activity (GO:0003899), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515)

GO Cellular Component (5): ubiquitin ligase complex (GO:0000151), nucleus (GO:0005634), nucleoplasm (GO:0005654), mediator complex (GO:0016592), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Metabolism of lipids	1
Metabolism	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
positive regulation of transcription by RNA polymerase II	2
positive regulation of DNA-templated transcription	2
transcription initiation at RNA polymerase II promoter	2
in utero embryonic development	1
anatomical structure development	1
regulation of DNA-templated transcription	1
protein modification by small protein conjugation	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
stem cell population maintenance	1
regulation of transcription by RNA polymerase II	1
transcription preinitiation complex assembly	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
transcription regulator activity	1
transcription coregulator activity	1
RNA biosynthetic process	1
5’-3’ RNA polymerase activity	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
intracellular protein-containing complex	1
transferase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
core mediator complex	1
nuclear protein-containing complex	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

1868 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED21	MED7	O43513	989
MED21	MED14	O60244	988
MED21	MED6	O75586	981
MED21	MED10	Q9BTT4	957
MED21	MED17	Q9NVC6	946
MED21	MED20	Q9H944	917
MED21	CCNC	P24863	893
MED21	MED31	Q9Y3C7	875
MED21	MED18	Q9BUE0	873
MED21	MED8	Q96G25	834
MED21	CDK8	P49336	828
MED21	MED29	Q9NX70	828
MED21	MED11	Q9P086	823
MED21	MED22	Q15528	811
MED21	MED9	Q9NWA0	803

IntAct

135 interactions, top by confidence:

A	B	Type	Score
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED21	MED9	psi-mi:“MI:0915”(physical association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED21	MED4	psi-mi:“MI:0915”(physical association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
MED26	MED7	psi-mi:“MI:0914”(association)	0.860
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
MED1	MED21	psi-mi:“MI:0915”(physical association)	0.850
MED21	MED7	psi-mi:“MI:0915”(physical association)	0.850
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
MED7	MED19	psi-mi:“MI:0914”(association)	0.840
MED11	MED19	psi-mi:“MI:0914”(association)	0.840
MED18	MED19	psi-mi:“MI:0914”(association)	0.840
CDK19	MED7	psi-mi:“MI:0914”(association)	0.800

BioGRID (378): MED21 (Two-hybrid), MED21 (Two-hybrid), BLOC1S6 (Two-hybrid), ZNF655 (Two-hybrid), SSC5D (Two-hybrid), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS), MED21 (Proximity Label-MS), MED21 (Proximity Label-MS), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS), MED21 (Affinity Capture-MS)

ESM2 similar proteins: A0A5G2QD80, A8E5U3, A9ULY7, O75934, Q13503, Q13561, Q16891, Q1HQF2, Q28DG8, Q28HX4, Q28Y46, Q2TBU8, Q3ZCF0, Q4R6N3, Q4V909, Q5EA95, Q5FW42, Q5PPY2, Q5R561, Q5RAX7, Q5RE46, Q5REX6, Q5RKQ0, Q5U1Z0, Q5ZKJ4, Q66J30, Q6AYH5, Q6DF11, Q6DFL5, Q6IRB3, Q6IVW0, Q6NY52, Q6PBE2, Q6TA25, Q7K2D2, Q7PZ25, Q7T3H1, Q7ZXA8, Q8BMG7, Q8BXG3

Diamond homologs: C0LU16, Q13503, Q2TBU8, Q4R6N3, Q5RE46, Q9CQ39, Q16RX1, Q61BU1, Q6BER6, Q7PTL0, Q7ZTI5, Q9W5P1, Q6C5U8, Q7S8C2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MED21	“form complex”	“Core mediator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 65 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	20	82.0×	2e-32
RSV-host interactions	20	65.2×	1e-30
Adipogenesis	20	65.2×	1e-30
Regulation of lipid metabolism by PPARalpha	20	58.7×	1e-29
Transcriptional regulation of white adipocyte differentiation	20	54.1×	6e-29
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	12	53.9×	7e-17
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	12	49.2×	2e-16
MicroRNA (miRNA) biogenesis	5	47.6×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	16	83.0×	3e-25
positive regulation of transcription initiation by RNA polymerase II	17	79.7×	3e-26
RNA polymerase II preinitiation complex assembly	16	75.0×	1e-24
transcription initiation at RNA polymerase II promoter	7	45.2×	2e-08
somatic stem cell population maintenance	6	25.6×	1e-05
transcription by RNA polymerase II	7	8.5×	1e-03
protein ubiquitination	8	5.7×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

14 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

614 predictions. Top by Δscore:

Variant	Effect	Δscore
12:27026411:T:A	acceptor_gain	1.0000
12:27026417:A:AG	acceptor_gain	1.0000
12:27026418:A:G	acceptor_gain	1.0000
12:27026530:AGAAG:A	donor_loss	1.0000
12:27026531:GAAG:G	donor_gain	1.0000
12:27026532:AAGG:A	donor_loss	1.0000
12:27026533:AG:A	donor_loss	1.0000
12:27026534:GGTAA:G	donor_loss	1.0000
12:27026535:GT:G	donor_loss	1.0000
12:27026536:T:A	donor_loss	1.0000
12:27027345:A:AG	acceptor_gain	1.0000
12:27027346:G:GG	acceptor_gain	1.0000
12:27027346:GA:G	acceptor_gain	1.0000
12:27027346:GAGT:G	acceptor_gain	1.0000
12:27027346:GAGTA:G	acceptor_gain	1.0000
12:27027446:AGG:A	donor_loss	1.0000
12:27027447:GGT:G	donor_loss	1.0000
12:27027448:G:GA	donor_loss	1.0000
12:27027448:G:GG	donor_gain	1.0000
12:27027449:T:G	donor_loss	1.0000
12:27028281:A:AG	acceptor_gain	1.0000
12:27028281:AAAG:A	acceptor_gain	1.0000
12:27028282:A:G	acceptor_gain	1.0000
12:27028283:A:AG	acceptor_gain	1.0000
12:27028283:A:T	acceptor_loss	1.0000
12:27028284:G:GG	acceptor_gain	1.0000
12:27022620:CGG:C	donor_loss	0.9900
12:27022622:G:GC	donor_loss	0.9900
12:27022622:G:GG	donor_gain	0.9900
12:27022623:T:G	donor_loss	0.9900

AlphaMissense

937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:27022586:G:C	D3H	1.000
12:27022602:T:A	L8H	1.000
12:27022602:T:C	L8P	1.000
12:27022610:G:C	A11P	1.000
12:27026421:T:C	L15P	1.000
12:27026440:T:A	N21K	1.000
12:27026440:T:G	N21K	1.000
12:27026441:G:C	A22P	1.000
12:27026442:C:A	A22D	1.000
12:27026447:G:A	G24R	1.000
12:27026447:G:C	G24R	1.000
12:27026448:G:A	G24E	1.000
12:27027361:T:A	F58I	1.000
12:27027361:T:C	F58L	1.000
12:27027363:T:A	F58L	1.000
12:27027363:T:G	F58L	1.000
12:27027365:C:A	A59E	1.000
12:27027371:T:C	L61P	1.000
12:27027374:T:A	I62N	1.000
12:27027385:G:C	A66P	1.000
12:27027416:T:C	L76S	1.000
12:27028337:T:C	L104P	1.000
12:27028370:T:C	L115P	1.000
12:27028387:G:C	A121P	1.000
12:27028391:T:C	L122P	1.000
12:27022586:G:A	D3N	0.999
12:27022587:A:T	D3V	0.999
12:27022589:C:T	R4W	0.999
12:27022593:T:A	L5H	0.999
12:27022593:T:C	L5P	0.999

dbSNP variants (sampled 300 via entrez): RS1000005200 (12:27023303 T>A), RS1000065298 (12:27024679 G>A,C), RS1000108541 (12:27030141 G>A,T), RS1000244688 (12:27036140 G>A), RS1000320793 (12:27031260 T>C), RS1000369261 (12:27036068 A>G), RS1000377855 (12:27031009 G>C), RS1000595181 (12:27036392 T>C), RS1000654685 (12:27024321 A>T), RS1001005326 (12:27024621 AG>A), RS1001284610 (12:27029480 A>G), RS1001355058 (12:27023469 G>A,T), RS1001649555 (12:27034722 T>C), RS1001771492 (12:27035798 A>C,G), RS1001939264 (12:27030750 A>G)

Disease associations

OMIM: gene MIM:603800 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005759_6	Dimensional psychopathology (Social)	4.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009100	social domain measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
bisphenol A	decreases expression, affects cotreatment, affects expression, increases abundance	2
Tretinoin	decreases expression	2
Particulate Matter	increases abundance, decreases expression	2
aristolochic acid I	decreases expression	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
dicrotophos	decreases expression	1
sodium arsenate	decreases expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	increases expression	1
ochratoxin A	decreases expression	1
cupric oxide	increases expression	1
tamibarotene	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
jinfukang	decreases expression	1
picoxystrobin	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Antimycin A	increases expression	1
Arsenic	increases abundance, increases expression	1
Cisplatin	affects response to substance	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Oils, Volatile	affects cotreatment, affects expression, increases abundance	1
Piroxicam	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.